IDEAYA Biosciences Reports Q1 2026 Financials, Highlights Positive Darovasertib Phase 2/3 Data and New AstraZeneca Collaboration

summarizeSummary

IDEAYA Biosciences reported Q1 2026 results, featuring positive Phase 2/3 clinical data for its lead asset, darovasertib, and a new collaboration with AstraZeneca, despite a wider net loss and the termination of a GSK partnership.

check_boxKey Events

• Positive Darovasertib Phase 2/3 Clinical Data

  The company reported positive topline Phase 2/3 data for darovasertib in metastatic uveal melanoma (OptimUM-02), demonstrating statistically significant improvements in progression-free survival and overall survival rate. An NDA submission is planned for H2 2026 under FDA's Real-Time Oncology Review program.

• New Clinical Collaboration with AstraZeneca

  In April 2026, IDEAYA entered a collaboration with AstraZeneca to evaluate IDE849 (DLL3 TOP1 ADC) in combination with Imfinzi (PD-L1 inhibitor) for extensive-stage small cell lung cancer in a Phase 1 trial.

• Wider Net Loss in Q1 2026

  IDEAYA Biosciences reported a net loss of $98.5 million for Q1 2026, compared to $72.2 million for Q1 2025, driven by increased research and development expenses.

• GSK Collaboration Termination and Program Discontinuation

  GSK terminated its collaboration for the Pol Theta (IDE705) and Werner Helicase (IDE275) programs, effective March 9, 2026. IDEAYA plans to discontinue development of these assets.

auto_awesomeAnalysis

IDEAYA Biosciences' Q1 2026 report provides a comprehensive update, with the most significant news being the positive topline Phase 2/3 data for darovasertib in metastatic uveal melanoma, which was also announced in a separate 8-K filing today. This data, showing statistically significant improvements in progression-free survival and overall survival rate, is a major de-risking event for their lead asset and paves the way for an NDA submission under FDA's Real-Time Oncology Review. While the company reported a wider net loss of $98.5 million for the quarter and increased R&D expenses, this is typical for a clinical-stage biotech advancing multiple programs. The termination of the GSK collaboration for two earlier-stage programs (IDE705 and IDE275) is a setback, but the initiation of several new Phase 1 trials and a new collaboration with AstraZeneca for IDE849 demonstrate continued pipeline development and strategic partnerships. The company maintains a strong cash position of $972.9 million, providing a runway of at least 12 months.